I mean they could go alone, but it’s incredibly risky. The PRV would likely go for 80-100M USD which would cover their P2B EMA + Dual FDA preclin/clin trials, but likely would dry up and not cover the later phase 2 trials for the FDA. I doubt ANP management want to try and tackle these pipelines by themselves, but I could be wrong.0
Chart, page-4320
-
-
- There are more pages in this discussion • 1,586 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $89.25M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 50193 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.0¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 50193 | 0.100 |
2 | 13179 | 0.099 |
2 | 113000 | 0.098 |
2 | 130927 | 0.097 |
1 | 10004 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.100 | 100000 | 1 |
0.105 | 207758 | 4 |
0.110 | 290000 | 4 |
0.115 | 601850 | 5 |
0.120 | 250642 | 7 |
Last trade - 07.03am 26/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
Day chart unavailable
The Watchlist
BPH
BPH ENERGY LTD
David Breeze, Managing Director and Executive Chairman
David Breeze
Managing Director and Executive Chairman
SPONSORED BY The Market Online